tirzepatide surpass Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT AMRA Used in Tirzepatide Analyses

McVey Neufeld KA, OMahony SM, Hoban AE, Waworuntu RV, Berg BM, Dinan TG, et al

In the Phase 2 obesity trial published in NEJM in 2023, retatrutide at the 12 mg weekly dose produced a mean placebo-adjusted body weight reduction of 22.1 percentage points (22.1% (24.2% arm) mean absolute reduction on the retatrutide arm) at 48 weeks (Jastreboff et al., NEJM, 2023)

Also, keep track of exactly when you take your medications

Great value Fast delivery Noticeable results Hope this helps someone out there

Anything below 95% purity introduces unknown impurities that could affect results or cause adverse reactions

Some links in this website are affiliate links, which means Mast Cell 360 may make a very small commission if you purchase through the link